This is a summary of the European public assessment report (EPAR) for Ritonavir Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ritonavir Mylan. For practical information about using Ritonavir Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older).
Therapeutic Area (MeSH)
ATC Code
J05AE03
ATC Item
N/A
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ritonavir | N/A | ritonavir |
EMA Name
Ritonavir Viatris (previously Ritonavir Mylan)
Medicine Name
Ritonavir Viatris (previously Ritonavir Mylan)
Aliases
N/ANo risk management plan link.
